Case Studies

Accelagen leads clinical trial for mRNA COVID-19 vaccine designed for immunosuppressed patients

Innovative biotech HelixNano has partnered with Accelagen to test the next generation of mRNA vaccines.

Accelagen Fast Tracks First-in-Human Anti-BKV Therapy Trial

When Swiss biotech sponsor Memo Therapeutics sought to trial a promising novel treatment for BK virus (Human polyomavirus 1), they turned to Accelagen.

Collaborating with Griffith University on a world-first clinical trial in the treatment of spinal cord injuries

Accelagen partners with Griffith University on a world-first trial using olfactory cells to treat spinal cord injuries and restore nerve function.

Negative to Positive: How Accelagen turned a double rejection into a successful medical technology ready to market

Accelagen secured ethics approval in 42 days for a US medical device company after two rejections through strategic regulatory expertise.

Australians benefit from first-ever cancer trial

Accelagen partners with ImaginAb for groundbreaking CD8 ImmunoPET cancer trials, offering non-invasive alternatives to tissue biopsies for immunotherapy patient

No results found.

There are no results with this criteria. Try changing your search.

Clinical Development

Regulatory affairs

Keep up to date with the latest news from Accelagen

Accelagen leads clinical trial for mRNA COVID-19 vaccine designed for immunosuppressed patients

Accelagen Fast Tracks First-in-Human Anti-BKV Therapy Trial

Collaborating with Griffith University on a world-first clinical trial in the treatment of spinal cord injuries

Negative to Positive: How Accelagen turned a double rejection into a successful medical technology ready to market

Australians benefit from first-ever cancer trial

Experience the Accelagen difference and unlock the future of human health